Literature DB >> 32308898

Mining Drugs and Indications for Suicide-Related Adverse Events.

Tiffany Ding1, Elizabeth S Chen1.   

Abstract

There has been a significant increase in suicide rates in the United States (U.S.) over the past two decades. Studies have highlighted the need for further exploration of suicide risk factors, particularly combinations of factors. In this study, a pharmacovigilance analysis was conducted to better understand drugs and indications as risk factors for suicide using data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and Adverse Event Open Learning through Universal Standardization (AEOLUS), a standardized version of FAERS. Association rule mining techniques were applied to 85,071 cases involving suicide-related adverse reactions and demographic subsets of these cases. Preliminary results reveal combinations of drugs and indications that may increase the likelihood of suicide, with certain combinations potentially affecting some demographic groups more than others. Further work is needed to validate the initial findings, explore subpopulations, and determine the broader implications for suicide prevention. ©2019 AMIA - All rights reserved.

Year:  2020        PMID: 32308898      PMCID: PMC7153138     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  21 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

2.  Mining multi-item drug adverse effect associations in spontaneous reporting systems.

Authors:  Rave Harpaz; Herbert S Chase; Carol Friedman
Journal:  BMC Bioinformatics       Date:  2010-10-28       Impact factor: 3.169

3.  Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response.

Authors:  F P Cappuccio; N D Markandu; D R Singer; G A MacGregor
Journal:  J Hypertens       Date:  1993-08       Impact factor: 4.844

Review 4.  Sex, gender, and pain: a review of recent clinical and experimental findings.

Authors:  Roger B Fillingim; Christopher D King; Margarete C Ribeiro-Dasilva; Bridgett Rahim-Williams; Joseph L Riley
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

5.  Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.

Authors:  Joseph F Hayes; Alexandra Pitman; Louise Marston; Kate Walters; John R Geddes; Michael King; David P J Osborn
Journal:  JAMA Psychiatry       Date:  2016-06-01       Impact factor: 21.596

6.  Exploration of the association rules mining technique for the signal detection of adverse drug events in spontaneous reporting systems.

Authors:  Chao Wang; Xiao-Jing Guo; Jin-Fang Xu; Cheng Wu; Ya-Lin Sun; Xiao-Fei Ye; Wei Qian; Xiu-Qiang Ma; Wen-Min Du; Jia He
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

7.  The SIDER database of drugs and side effects.

Authors:  Michael Kuhn; Ivica Letunic; Lars Juhl Jensen; Peer Bork
Journal:  Nucleic Acids Res       Date:  2015-10-19       Impact factor: 16.971

Review 8.  Novel statistical tools for monitoring the safety of marketed drugs.

Authors:  J S Almenoff; E N Pattishall; T G Gibbs; W DuMouchel; S J W Evans; N Yuen
Journal:  Clin Pharmacol Ther       Date:  2007-05-30       Impact factor: 6.875

9.  A curated and standardized adverse drug event resource to accelerate drug safety research.

Authors:  Juan M Banda; Lee Evans; Rami S Vanguri; Nicholas P Tatonetti; Patrick B Ryan; Nigam H Shah
Journal:  Sci Data       Date:  2016-05-10       Impact factor: 6.444

10.  Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project.

Authors:  Susanne Stübner; Renate Grohmann; Waldemar Greil; Xueqiong Zhang; Bruno Müller-Oerlinghausen; Stefan Bleich; Eckart Rüther; Hans-Jürgen Möller; Rolf Engel; Peter Falkai; Sermin Toto; Siegfried Kasper; Alexandra Neyazi
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.